--- title: "Fingerprint Cards AB Bets on Merger-Led Turnaround" type: "News" locale: "en" url: "https://longbridge.com/en/news/286333864.md" description: "Fingerprint Cards AB reported a mixed Q1 earnings call, highlighting a 4% revenue growth and a 62.3% gross margin, despite challenges like negative EBITDA and tight cash. The company is banking on a merger with Precise Biometrics to address its subscale cost base, aiming for significant annual cost synergies. AllKey platform is emerging as a key growth driver, representing 75% of the Q1 pipeline. However, the company faces liquidity pressures and must successfully execute the merger to achieve sustainable profitability." datetime: "2026-05-14T00:24:20.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/286333864.md) - [en](https://longbridge.com/en/news/286333864.md) - [zh-HK](https://longbridge.com/zh-HK/news/286333864.md) --- # Fingerprint Cards AB Bets on Merger-Led Turnaround Fingerprint Cards Ab (($SE:FING.B)) has held its Q1 earnings call. Read on for the main highlights of the call. ### Claim 55% Off TipRanks - Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions - Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks Fingerprint Cards AB’s latest earnings call mixed cautious realism with growing optimism as management highlighted double‑digit constant‑currency growth, a standout 62.3% gross margin and accelerating traction for its AllKey platform. Yet the discussion repeatedly returned to the company’s subscale cost base, negative EBITDA and tight cash, underscoring how much now rides on a newly approved merger and execution on its expanding pipeline. ## Top‑Line Momentum Amid Currency Headwinds Revenue in Q1 2026 grew 4% in reported terms and 21% in constant currency, signaling solid underlying demand despite FX pressure. Management framed this as evidence that the core franchise is recovering, with growth outpacing the cost base but not yet sufficient to offset the burden of being a small listed global player. ## Gross Margins Signal Healthy Pricing Power Core product gross margin reached 62.3%, above both Q1 2025 and the full‑year 2025 average, reflecting a favorable mix and firm pricing. The strong margin profile suggests Fingerprint Cards is competing more on technology and value than on price, giving it some cushion as it works through its current scale and liquidity challenges. ## AllKey Emerges as the Growth Engine AllKey dominated new business activity, representing 75% of Q1 pipeline by revenue and with 60% of that AllKey pipeline coming from new customers. Management emphasized that AllKey deals deliver roughly three times the average selling price of legacy sensor contracts and that the new AllKey software platform widens system‑level use cases, setting up a structural shift in the revenue mix. ## Merger with Precise Biometrics Targets Scale Shareholders approved the merger with Precise Biometrics at the end of April, framing it as the strategic answer to the company’s subscale economics. Management detailed at least SEK 45 million in annual operating cost synergies and projected that the combined group can sustain double‑digit revenue growth and double‑digit EBITDA margins once integration is executed. ## Fast Payback on Synergies to Lift Profitability The synergy case is unusually punchy, with management estimating SEK 25 million in cash implementation costs to unlock SEK 45 million in annual savings, implying roughly a seven‑month payback. If delivered on schedule, this would swing the combined company from a pro forma 2025 EBITDA loss of SEK 19 million toward attractive mid‑teens margins in short order. ## Complementary Capabilities and Low Integration Risk Fingerprint Cards brings hardware expertise while Precise contributes software and multimodal biometrics, creating a more complete offering and wider go‑to‑market reach. Integration planning is already underway with a designated leader and a closing target around mid‑July, and management played down cultural or operational friction, presenting the merger as largely additive rather than disruptive. ## Operational Discipline Supports Lean Growth The company kept operating expenses in check with headcount around 50 while still delivering revenue growth, highlighting process improvements and AI tools to boost productivity. This lean setup is meant to ensure that incremental revenue increasingly drops to the bottom line post‑merger, provided the combined entity can reach the necessary scale to amortize public‑company overheads. ## EBITDA Still Negative Despite Progress Q1 EBITDA came in at negative SEK 14.1 million, including about SEK 3 million of non‑recurring merger‑related costs, underlining that the business is not yet self‑funding. On a combined basis with Precise, pro forma 2025 EBITDA was around negative SEK 19 million before synergies, making cost extraction and revenue growth critical to reach the promised double‑digit margin profile. ## Free Cash Flow and Liquidity Remain Pressure Points Free cash flow was negative SEK 13.2 million in Q1 2026, leaving cash at just SEK 18.2 million at quarter‑end and highlighting a constrained near‑term liquidity position. Until either revenues ramp or merger synergies drop through, investors will be watching burn closely and assessing whether the balance sheet can comfortably bridge the transformation period. ## Scale Challenge Highlights Need for Consolidation Management was explicit that the company faces a scale problem, pointing to an effective fixed operating‑expense floor of about SEK 90 million a year for a global listed business. With the current revenue base below what is needed to absorb that overhead, they argued that growth and consolidation via the Precise merger are essential to unlocking sustainable profitability. ## Execution Risk Around Synergies and Timing The profitability story now hinges on successfully delivering the SEK 45 million synergy program and closing the merger on schedule, with some regulatory steps still pending. Any delays, integration complexity or lower‑than‑planned savings could push out the timeline for breakeven and test investor patience given the already thin cash buffer. ## Uncertain Conversion from Pipeline to Revenues While AllKey’s 75% share of new pipeline and strong new‑client mix look impressive, management conceded that conversion timing is hard to predict, especially for larger legacy sensor customers. They pointed to 2027–2028 as the likely window for a pronounced AllKey‑driven revenue inflection, leaving a multi‑year execution runway before the full benefits show in reported numbers. ## Guidance and Outlook for the Combined Group Management guided that the merged Fingerprint Cards–Precise entity should deliver double‑digit revenue growth and double‑digit EBITDA margins, with adjusted pro forma EBITDA targeted around 17% after synergies. Based on roughly SEK 156–160 million of combined 2025 revenue and a pre‑synergy EBITDA loss, the path to that margin profile depends on closing the deal by mid‑July, realizing SEK 45 million in annual savings for about SEK 25 million in cash costs and accelerating the AllKey shift toward a higher‑value mix by 2027–2028. The earnings call painted a company at an inflection point, balancing solid operational traction and a compelling merger‑driven synergy story against short‑term losses and tight liquidity. For investors, the key takeaways are strengthening margins and product momentum, a credible if ambitious consolidation plan and a clear execution checklist that will determine whether today’s promise turns into durable profitability over the next few years. ### Related Stocks - [159849.CN](https://longbridge.com/en/quote/159849.CN.md) - [IBB.US](https://longbridge.com/en/quote/IBB.US.md) - [BBH.US](https://longbridge.com/en/quote/BBH.US.md) - [159992.CN](https://longbridge.com/en/quote/159992.CN.md) - [159859.CN](https://longbridge.com/en/quote/159859.CN.md) - [LABU.US](https://longbridge.com/en/quote/LABU.US.md) - [BIS.US](https://longbridge.com/en/quote/BIS.US.md) - [BIB.US](https://longbridge.com/en/quote/BIB.US.md) - [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md) - [159837.CN](https://longbridge.com/en/quote/159837.CN.md) - [FBT.US](https://longbridge.com/en/quote/FBT.US.md) - [516930.CN](https://longbridge.com/en/quote/516930.CN.md) - [XBI.US](https://longbridge.com/en/quote/XBI.US.md) - [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md) - [516500.CN](https://longbridge.com/en/quote/516500.CN.md) ## Related News & Research - [Tiziana Announces New Positive Clinical Data For Intranasal Foralumab In Non-Active Secondary Progressive Multiple Sclerosis](https://longbridge.com/en/news/286899753.md) - [Genprex data shows gene therapy reverses hyperglycemia in T2D mice at ASGCT](https://longbridge.com/en/news/286414681.md) - [Relay's treatment shown to shrink vascular malformations in mid-stage trial](https://longbridge.com/en/news/286890329.md) - [NeOnc Advances Glioma Programs and Strengthens Financial Position](https://longbridge.com/en/news/286826865.md) - [Wave Life Sciences posts positive RestorAATion-2 data; WVE-006 restores M-AAT, cuts Z-AAT, supports monthly dosing](https://longbridge.com/en/news/286818220.md)